In a surprising move, Gilead Sciences (GILD) early next year will begin selling so-called authorized generic versions of its two leading hepatitis C treatments — Epclusa and Harvoni — at significantly lower prices that the company claims will offer “substantial savings” to Medicaid and other patients.
The effort, which was met with intrigue on Wall Street but skepticism among patient advocates, comes as Gilead struggles to compete in a hepatitis C market that it once dominated with sky-high prices before rivals began undercutting its market share with lower pricing.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
Ah, a wonderful phrase – “another round of pricing flux” – as if the market pricing system weren’t acknowledged as already “Fluxxed,” as it were,